文献速递其他结缔组织病

自体非清髓性造血干细胞移植治疗弥漫性皮肤型系统性硬化症:在前瞻性单臂试验中识别毒性的疾病危险因素与长期结局

Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation for Diffuse Cutaneous Systemic Sclerosis: Identifying Disease Risk Factors for Toxicity and Long-Term Outcomes in a Prospective, Single-Arm Trial.
PubMed 文献 · Arthritis Rheumatol · 2025-01-14

这项前瞻性单臂试验入组20例高危系统性硬化症患者,采用环磷酰胺200 mg/kg联合马抗胸腺细胞球蛋白预处理,输注未经修饰的自体外周血干细胞,移植后2个月起用吗替麦考酚酯维持。移植后5年总生存率点估计为85%(95%CI 60.4%-94.9%),无事件生存率为75%(95%CI 50%-88.7%)。作者认为该方案结局与CD34+选择移植试验可比,并识别出移植前低eGFR可能是移植后不良结局的危险因素。

要点

  • 20例高危系统性硬化症患者接受环磷酰胺200 mg/kg联合马抗胸腺细胞球蛋白预处理、未经修饰自体外周血干细胞输注及移植后吗替麦考酚酯维持。
  • 移植后5年总生存率点估计为85%(95%CI 60.4%-94.9%),无事件生存率为75%(95%CI 50%-88.7%)。
  • 9例抗RNA聚合酶III抗体阳性患者中4例有硬皮病肾危象史且入组时eGFR处于最低四分位,该4例均在移植后早期出现迁延性器官衰竭/死亡。

核心结论

  • 作者观察到,采用环磷酰胺200 mg/kg联合马抗胸腺细胞球蛋白预处理、未经修饰外周血干细胞及移植后吗替麦考酚酯维持的自体造血干细胞移植,患者总生存率和无事件生存率良好,与采用CD34+选择移植的试验可比。
  • 作者识别出移植前低eGFR可能是自体造血干细胞移植后不良结局的危险因素。

研究设计与样本

  • 前瞻性单臂试验,入组20例高危系统性硬化症患者。
  • 预处理为环磷酰胺200 mg/kg联合马抗胸腺细胞球蛋白,随后输注未经修饰的自体外周血干细胞,移植后2个月起开始吗替麦考酚酯维持。

主要发现

  • 移植后5年总生存率点估计为85%(95%CI 60.4%-94.9%),无事件生存率点估计为75%(95%CI 50%-88.7%)。
  • 存活患者移植后中位随访7.5年(范围5.6-11.6年)。
  • 8例患者(40%)在移植后早期需要重症监护治疗。
  • 2例患者(10%)发生早期移植相关死亡。
  • 5例患者在移植后出现系统性硬化症复发/进展。

临床怎么用

  • 作者认为,采用环磷酰胺200 mg/kg联合马抗胸腺细胞球蛋白预处理、未经修饰外周血干细胞及移植后吗替麦考酚酯维持的自体造血干细胞移植,可获得良好的总生存率和无事件生存率,与CD34+选择移植试验可比。
  • 作者识别出移植前低eGFR可能是自体造血干细胞移植后不良结局的危险因素。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Two randomized trials for patients with diffuse systemic sclerosis (SSc) demonstrated an overall survival (OS) and event-free survival (EFS) advantage of autologous hematopoietic stem cell transplantation (AHSCT) using CD34+ selected peripheral blood stem cells (PBSCs) compared with monthly cyclophosphamide (CY). We asked if an unmodified PBSC graft followed by maintenance mycophenolate mofetil (MMF) after AHSCT, instead of a CD34+ selected graft, could provide comparable AHSCT outcomes. METHODS: Twenty patients with high-risk SSc were enrolled in a prospective, single-arm trial with CY 200 mg/kg and horse antithymocyte globulin (ATG; CY200/ATG), followed by unmanipulated autologous PBSC, and then MMF maintenance starting at 2 months after AHSCT. RESULTS: Point estimates of OS and EFS at 5 years after AHSCT were 85% (95% confidence interval [CI] 60.4%-94.9%) and 75% (95% CI 50%-88.7%), respectively. Median follow-up was 7.5 years (range 5.6-11.6) after transplant for living patients. Eight patients (40%) required intensive care unit treatment early after transplant. Early transplant-related mortality occurred in two patients (10%). Five patients developed relapse/progression of SSc after AHSCT. Four of nine patients with anti-RNA polymerase III antibodies had prior scleroderma renal crisis and the lowest quartile of estimated glomerular filtration rate (eGFR) on study entry; all four patients developed prolonged organ failure/death early after transplant. CONCLUSION: We observed favorable OS and EFS after AHSCT for patients with SSc, using CY200/ATG, unmanipulated PBSCs, and MMF posttransplant maintenance, which was comparable to trials with CD34+ graft selection. We identified a possible risk factor, pretransplant low eGFR, for adverse outcomes after AHSCT.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Georges GE, Khanna D, Wener MH, et al. Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation for Diffuse Cutaneous Systemic Sclerosis: Identifying Disease Risk Factors for Toxicity and Long-Term Outcomes in a Prospective, Single-Arm Trial. Arthritis Rheumatol. 2025. PMID: 39624016. doi:10.1002/art.43072

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。